PEARSS Study
Research type
Research Study
Full title
Prospective Evaluation of mid-term outcomes following Aortic valve Replacement with Smaller Supra-annular stented bioprostheses (PEARSS).
IRAS ID
196630
Contact name
Geoff Tsang
Contact email
Sponsor organisation
University Hospital Southampton NHS Foundation Trust
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Aortic valve replacement is the treatment of choice for patients with narrowing of the aortic valve; a major heart valve. Valves made from animals tissues are very widely used. They don't require blood thinning medications. Different types are present in the market with different designs. The decision to use one or other is up to the surgeons. The choice is based on the anatomy of the patient, data on longevity of the valve, ease for implantation and best outcome for the patient.
We have recently looked at out preliminary experience with one type of valves called (Trifecta), and found that this valve has favorable advantages compared to one of the older well established valves (Magna ease). The main benefit is that when comparing the 2 valves of similar ring size, the Trifecta valves opens more widely allowing more blood to go, and therefore, better function of the heart and potentially better survival of the patients. However the older Magna ease has been shown to function for many years. In order to help surgeons make better choices for the best benefit of the patients, there is a need to for a study to scientifically compare the two valves.
REC name
West of Scotland REC 5
REC reference
16/WS/0150
Date of REC Opinion
8 Aug 2016
REC opinion
Further Information Favourable Opinion